A process for the conversion of glycolaldehyde with an aminating agent in the presence of hy-5 drogen and of a catalyst, wherein the conversion is carried out in the gas phase.

A process for the conversion of glycolaldehyde with an aminating agent in the presence of hy-5 drogen and of a catalyst, wherein the conversion is carried out in the gas phase.

A method of making a functionalized fluorinated monomer for use in making oligomers and polymers that can be used to improve surface properties of polymer-derived systems, such as coatings. The method of making a functionalized fluorinated monomer includes reacting at least one fluorinated nucleophilic reactant, such as a fluorinated alcohol, with at least one compound containing at least one epoxide group. Other methods include reaction of a fluorinated alcohol with a cyclic carboxylic anhydride. In another embodiment, a method includes reacting a fluorinated mesylate, tosylate or triflate with an amine, alkoxide or phenoxide. In other embodiments, the method includes reacting a fluorinated alcohol with an alkyl halide, or reacting a fluorinated alkyl halide with an amine. The functionalized fluorinated monomers may be used as intermediates and reacted to modify the functional groups thereon. Further, the functionalized fluorinated monomers may be reacted to form polymers or oligomers, or with polymers or oligomers having functional groups to modify the polymer or oligomer through the functional group thereon.

A method of making a functionalized fluorinated monomer for use in making oligomers and polymers that can be used to improve surface properties of polymer-derived systems, such as coatings. The method of making a functionalized fluorinated monomer includes reacting at least one fluorinated nucleophilic reactant, such as a fluorinated alcohol, with at least one compound containing at least one epoxide group. Other methods include reaction of a fluorinated alcohol with a cyclic carboxylic anhydride. In another embodiment, a method includes reacting a fluorinated mesylate, tosylate or triflate with an amine, alkoxide or phenoxide. In other embodiments, the method includes reacting a fluorinated alcohol with an alkyl halide, or reacting a fluorinated alkyl halide with an amine. The functionalized fluorinated monomers may be used as intermediates and reacted to modify the functional groups thereon. Further, the functionalized fluorinated monomers may be reacted to form polymers or oligomers, or with polymers or oligomers having functional groups to modify the polymer or oligomer through the functional group thereon.

The invention relates to the field of pharmaceutical synthesis, in particular to the preparation method of hexahydrofuro-furanol derivative, intermediates thereof and preparation methods thereof. The preparation methods comprises the steps of halogenation reaction, acylation reaction, enzymatic reduction reaction, reaction with amine compounds, reduction ring closure reaction (A1, A2, B, Cp1, C.sub.L, Cf)

##STR00001##

wherein, R.sub.1, R.sub.2, R.sub.3 are hydrogen or hydroxy protecting groups; R.sub.4 and R.sub.5 are the same or different and are phenyl, alkyl or substituted phenyl. In the preparation process of hexahydrofuro-furanol derivatives, the chirality is constructed by enzymatic method, and the product can be prepared with very high optical purity by adopting such technical means. The preparation method can be used to prepare the key intermediate, (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]-3-ol, of Darunavir, in commercial production, which is a very economical route suitable for industrial production.

The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator. ##STR00001##

The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator. ##STR00001##

A process for preparing hydroxyethyl ethylene amines and/or ethylene urea derivatives thereof includes reacting monoethylene glycol with an amine-functional compound having at least two —NH— units, of which at least one is selected from the group of primary amine groups and cyclic secondary amine groups, in the presence of a carbon oxide-delivering agent. The amine-functional compound includes at least one —NH—CH2-CH2-NH— unit, wherein one or more —NH—CH2-CH2-NH— units in the amine-functional compound may be present in the form of piperazine moieties or ethylene urea moieties. The molar ratio of amine-functional compound to monoethylene glycol is in the range of 0.2:1 to 1.5:1 and the molar ratio of carbon oxide-delivering agent to —NH—CH2-CH2-NH— units in the amine-functional compound is at least 0.5:1. The process allows the conversion of monoethylene glycol into ethanol amines in the absence of metals-containing catalysts and without using ammonia.

A process for preparing hydroxyethyl ethylene amines and/or ethylene urea derivatives thereof includes reacting monoethylene glycol with an amine-functional compound having at least two —NH— units, of which at least one is selected from the group of primary amine groups and cyclic secondary amine groups, in the presence of a carbon oxide-delivering agent. The amine-functional compound includes at least one —NH—CH2-CH2-NH— unit, wherein one or more —NH—CH2-CH2-NH— units in the amine-functional compound may be present in the form of piperazine moieties or ethylene urea moieties. The molar ratio of amine-functional compound to monoethylene glycol is in the range of 0.2:1 to 1.5:1 and the molar ratio of carbon oxide-delivering agent to —NH—CH2-CH2-NH— units in the amine-functional compound is at least 0.5:1. The process allows the conversion of monoethylene glycol into ethanol amines in the absence of metals-containing catalysts and without using ammonia.

A two-step one-pot process for reacting glycolaldehyde with an aminating agent in the presence of a reactive organic fluid for instance a reactive solvent is provided. The first step comprises of contacting glycolaldehyde with an aminating agent in the presence of a reactive fluid for instance a reactive solvent under inert atmosphere to produce unsaturated intermediates, and reacting the reaction mixture obtained in step 1 with hydrogen in the presence of a supported hydrogenation catalyst in a second step.